Elizabeth M Brunt1, David E Kleiner2, Laura A Wilson3, Arun J Sanyal4, Brent A Neuschwander-Tetri5. 1. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO. 2. Laboratory of Pathology, National Cancer Institute, Bethesda, MD. 3. Johns Hopkins University, Baltimore, MD. 4. Virginia Commonwealth University School of Medicine, Richmond, VA. 5. Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO.
Abstract
Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH). This study sought associations between observed improvements in fibrosis with improvement in specific histologic features, nonalcoholic fatty liver disease activity score (NAS) ≥2, diagnostic category, and primary histologically based outcomes of two adult NASH treatment trials. The primary outcome for the study was fibrosis improvement from baseline to end of treatment, defined as a 1-point or more improvement in fibrosis stage. This is a retrospective analysis of biopsy data collected from the NASH Clinical Research Network Pathology Committee of Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH Trial (PIVENS) and Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial (FLINT) baseline and final biopsies. Treatment group-adjusted univariable and multivariable logistic regression models related improvement in fibrosis to improvements in other histologic variables, resolution of steatohepatitis, and improvement in the NAS ≥2. In PIVENS 221 subjects had baseline and 96-week biopsies, and in FLINT 200 subjects had baseline and 72-week biopsies. Improvement in fibrosis was found in 38% of PIVENS and 29% of FLINT biopsies; fibrosis improvement was more likely in treated than placebo subjects in both studies. Controlling for treatment group, fibrosis improvement was associated most strongly with resolution of NASH (PIVENS, odds ratio [OR], 3.9; 95% confidence interval [CI] 2.0-7.6; P < 0.001; FLINT, OR, 8.0; 95% CI 3.1-20.9; P < 0.001), and improved NAS by ≥2 (PIVENS, OR, 2.4; 95% CI 1.3-4.3; P = 0.003; FLINT, OR, 4.2; 95% CI 2.1-8.3; P < 0.001). Improvement in histologic features associated with improved fibrosis for both studies included steatosis, ballooning, Mallory-Denk bodies, and portal, but not lobular, inflammation. Conclusion: These findings support a strong link between histologic resolution of steatohepatitis with improvement in fibrosis in NASH.
Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH). This study sought associations between observed improvements in fibrosis with improvement in specific histologic features, nonalcoholic fatty liver disease activity score (NAS) ≥2, diagnostic category, and primary histologically based outcomes of two adult NASH treatment trials. The primary outcome for the study was fibrosis improvement from baseline to end of treatment, defined as a 1-point or more improvement in fibrosis stage. This is a retrospective analysis of biopsy data collected from the NASH Clinical Research Network Pathology Committee of Pioglitazone versus Vitamin E versus Placebo for the Treatment of NondiabeticPatients with NASH Trial (PIVENS) and Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial (FLINT) baseline and final biopsies. Treatment group-adjusted univariable and multivariable logistic regression models related improvement in fibrosis to improvements in other histologic variables, resolution of steatohepatitis, and improvement in the NAS ≥2. In PIVENS 221 subjects had baseline and 96-week biopsies, and in FLINT 200 subjects had baseline and 72-week biopsies. Improvement in fibrosis was found in 38% of PIVENS and 29% of FLINT biopsies; fibrosis improvement was more likely in treated than placebo subjects in both studies. Controlling for treatment group, fibrosis improvement was associated most strongly with resolution of NASH (PIVENS, odds ratio [OR], 3.9; 95% confidence interval [CI] 2.0-7.6; P < 0.001; FLINT, OR, 8.0; 95% CI 3.1-20.9; P < 0.001), and improved NAS by ≥2 (PIVENS, OR, 2.4; 95% CI 1.3-4.3; P = 0.003; FLINT, OR, 4.2; 95% CI 2.1-8.3; P < 0.001). Improvement in histologic features associated with improved fibrosis for both studies included steatosis, ballooning, Mallory-Denk bodies, and portal, but not lobular, inflammation. Conclusion: These findings support a strong link between histologic resolution of steatohepatitis with improvement in fibrosis in NASH.
Authors: Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo Journal: Lancet Date: 2014-11-07 Impact factor: 79.321
Authors: G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck Journal: N Engl J Med Date: 2010-04-28 Impact factor: 91.245
Authors: Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed Journal: Gastroenterology Date: 2014-11-25 Impact factor: 22.682
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Heather M Patton; Joel E Lavine; Mark L Van Natta; Jeffrey B Schwimmer; David Kleiner; Jean Molleston Journal: Gastroenterology Date: 2008-09-03 Impact factor: 22.682
Authors: Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji Journal: Can Liver J Date: 2022-02-04
Authors: Joseph Carpenter; Gang Wu; Ying Wang; Erica M Cook; Tao Wang; Doree Sitkoff; Karen A Rossi; Kathy Mosure; Xiaoliang Zhuo; Gary G Cao; Milinda Ziegler; Anthony V Azzara; Jack Krupinski; Matthew G Soars; Bruce Alan Ellsworth; Dean A Wacker Journal: ACS Med Chem Lett Date: 2021-08-05 Impact factor: 4.632
Authors: Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny Journal: FASEB J Date: 2020-04-18 Impact factor: 5.191
Authors: Rish K Pai; David E Kleiner; John Hart; Oyedele A Adeyi; Andrew D Clouston; Cynthia A Behling; Dhanpat Jain; Sanjay Kakar; Mayur Brahmania; Lawrence Burgart; Kenneth P Batts; Mark A Valasek; Michael S Torbenson; Maha Guindi; Hanlin L Wang; Veeral Ajmera; Leon A Adams; Claire E Parker; Brian G Feagan; Rohit Loomba; Vipul Jairath Journal: Aliment Pharmacol Ther Date: 2019-10-03 Impact factor: 8.171
Authors: Stephen A Harrison; Peter J Ruane; Bradley L Freilich; Guy Neff; Rashmee Patil; Cynthia A Behling; Chen Hu; Erica Fong; Brittany de Temple; Erik J Tillman; Timothy P Rolph; Andrew Cheng; Kitty Yale Journal: Nat Med Date: 2021-07-08 Impact factor: 53.440